Interview: Dr. Anthony Atala discusses the future of regenerative medicine

Longeveron Aging Frailty Phase 2b Trial

Longeveron is currently enrolling subjects in its Phase 2b multi-center clinical trial designed to test the safety and efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) for the treatment of subjects with clinically diagnosed with Aging Frailty. This is the only...
Interview: Dr. Anthony Atala discusses the future of regenerative medicine

Longeveron Alzheimer’s Disease Trial

Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients with Alzheimer’s Disease. Longeveron’s Phase I, prospective, randomized, placebo-controlled, double-blinded study is designed to test the safety and efficacy of Longeveron Mesenchymal Stem...